Among patients receiving high-risk chemotherapy regimens, patients with breast cancer were significantly more likely to receive G-CSF as primary prophylaxis than patients with non–small-cell lung carcinoma (NSCLC). The gene discussed is CSF3; the disease is non-small cell lung carcinoma.